
RNTX Stock Forecast & Price Target
RNTX Analyst Ratings
Bulls say
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company with promising clinical assets, including LTI-03 and LTI-01, which are positioned to address significant unmet needs in orphan pulmonary and fibrosis indications. Recent data indicating increased sRAGE levels in LTI-03 recipients suggest favorable pharmacodynamic activity, contributing to the stock’s perceived favorable risk-reward profile among investors. The company's potential best-in-class pipeline, targeting areas with limited or inadequate treatment options, enhances the outlook for substantial market opportunities and opportunistic growth over the next 12 months.
Bears say
Rein Therapeutics Inc. has experienced significant share price declines in 2025, with a 50% decrease year-to-date compared to a mere 3.5% decline in the broader XBI index, largely due to the company's decision to pause enrollment in U.S. clinical trials. This pause has introduced uncertainty regarding the progress and viability of its product candidates, particularly LTI-03, which is aimed at treating Idiopathic Pulmonary Fibrosis (IPF). Furthermore, the observed correlation between lower serum receptor for advanced glycation end-products (sRAGE) levels and poor survival rates in IPF patients raises concerns about the clinical efficacy and market potential of Rein's therapeutic developments.
This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNTX Analyst Forecast & Price Prediction
Start investing in RNTX
Order type
Buy in
Order amount
Est. shares
0 shares